Level Biotechnology

Level Biotechnology Intangible Assets

The Intangible Assets of Level Biotechnology (3118.TWO) as of Nov 4, 2026 is 23,000.00 TWD. In the previous year, Intangible Assets was 48,000.00 TWD — a change of -52.08% (lower).

Intangible Assets

23,000.00TWD

YoY

-52.08%

Last updated:

Intangible Assets of Level Biotechnology is 2022 23,000.00 TWD. Intangible Assets of Level Biotechnology was 2021 48,000.00 TWD. It decreases by -52.08% lower compared to the previous year.

The Level Biotechnology Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2015
203,000.00 TWD
Jan 1, 2016
177,000.00 TWD
Jan 1, 2017
151,000.00 TWD
Jan 1, 2018
125,000.00 TWD
Jan 1, 2019
99,000.00 TWD
Jan 1, 2020
74,000.00 TWD
Jan 1, 2021
48,000.00 TWD
Jan 1, 2022
23,000.00 TWD
The Level Biotechnology Intangible Assets history
YEARIntangible AssetsYoY
23,000.00TWD-52.08%
48,000.00TWD-35.14%
74,000.00TWD-25.25%
99,000.00TWD-20.80%
125,000.00TWD-17.22%
151,000.00TWD-14.69%
177,000.00TWD-12.81%
203,000.00TWD-11.35%
229,000.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Level Biotechnology Stock analysis

What does Level Biotechnology do? Level Biotechnology, Inc. generates revenue through the sale of biotechnological services and products. The company offers cell culture series, immune protein series, gene nucleic acid and molecular biology series, and instrument series to customers in the domestic market. Preclinical testing services, including genetic toxicity testing, general toxicology testing, reproductive toxicology testing, pharmacokinetic testing, and biocompatibility testing, are also provided as key revenue streams. Domestic market buyers primarily include research institutions and pharmaceutical companies seeking advanced biotech solutions. The firm's product portfolio targets the biotechnology and pharmaceutical sectors, with a focus on domestic customers. Cell culture series and molecular biology series are essential for laboratory research, while immune protein series supports immunological studies. Preclinical testing services cater to pharmaceutical firms requiring regulatory compliance for drug development. All products and services are distributed exclusively within the domestic market, ensuring focused market penetration and customer relationships. Level Biotechnology's revenue model relies on consistent demand for biotech products and testing services from domestic clients. The company's domestic market distribution strategy allows for tailored service delivery and strong client retention. By specializing in cell culture, molecular biology, and preclinical testing, Level Biotechnology maintains a competitive edge in the local biotech industry. Level Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Level Biotechnology stock

Intangible Assets of Level Biotechnology is 23,000.00 TWD in 2022.

Intangible Assets of Level Biotechnology changed from 48,000.00 TWD to 23,000.00 TWD, representing a -52.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Level Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Level Biotechnology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Level Biotechnology

All Key Metrics — Level Biotechnology